Patients with non-small cell lung cancer (NSCLC) with pleural dissemination have very limited survivals often of just 6-9 months. Prior reports of aggressive surgical resection of pleural metastases have shown no consistent improvements in overall survival and very high rates of local recurrences. Based on this and the generally very diffuse pleural dissemination seen in patients, chemotherapy and palliative interventions are standard of care. By attempting to sterile microscopic residual disease after surgical resection, intraoperative photodynamic therapy (PDT) could improve local pleural control and overall survival compared with surgery alone for patients with NSCLC with pleural metastasis. Prior attempts to demonstrate an improvement in clinical outcomes with PDT as an intraoperative adjuvant combined with definitive surgery to treat pleural malignancies have not been successful, perhaps due, in part, to limited ability to perform real-time dosimetry and ensure adequate and even light distribution throughout the chest cavity. A stratified phase II trial assessed the efficacy of definitive surgery and intraoperative PDT with real-time dosimetry in patients with NSCLC with pleural dissemination demonstrated prolonged local control and a higher than expected 21.7-month median survival from the time of surgery and PDT among 22 enrolled patients. This is the first ever report describing optimal methods, techniques, and dosimetry that could be used to safely and reproducibly deliver intraoperative PDT to the chest cavity as part of multimodality therapy for NSCLC with pleural metastasis.
ASBRTACT
Patients with non-small cell lung cancer (NSCLC) with pleural dissemination have very limited survivals often of just 6-9 months. Prior reports of aggressive surgical resection of pleural metastases have shown no consistent improvements in overall survival and very high rates of local recurrences. Based on this and the generally very diffuse pleural dissemination seen in patients, chemotherapy and palliative interventions are standard of care. By attempting to sterile microscopic residual disease after surgical resection, intraoperative photodynamic therapy (PDT) could improve local pleural control and overall survival compared with surgery alone for patients with NSCLC with pleural metastasis. Prior attempts to demonstrate an improvement in clinical outcomes with PDT as an intraoperative adjuvant combined with definitive surgery to treat pleural malignancies have not been successful, perhaps due, in part, to limited ability to perform real-time dosimetry and ensure adequate and even light distribution throughout the chest cavity. A stratified phase II trial assessed the efficacy of definitive surgery and intraoperative PDT with real-time dosimetry in patients with NSCLC with pleural dissemination demonstrated prolonged local control and a higher than expected 21.7-month median survival from the time of surgery and PDT among 22 enrolled patients. This is the first ever report describing optimal methods, techniques, and dosimetry that could be used to safely and reproducibly deliver intraoperative PDT to the chest cavity as part of multimodality therapy for NSCLC with pleural metastasis.
INTRODUCTION
It is estimated that 224,210 people in the United States will be diagnosed with lung cancer in 2014, of which approximately 86% will be non-small cell lung cancer (NSCLC). [1] [2] [3] Approximately two in five patients diagnosed with NSCLC present with metastatic disease [2] [3] , and this number may be increasing with the more widespread use of PET/CT scans. [4] Patients are most commonly diagnosed with stage IV disease due to the presence of extrathoracic metastases. However, pleural dissemination by tumor is also designated as stage IV disease [5] due to its grave prognosis.
The pleural space exists between two layers of mesothelioma that envelop both lungs, termed the visceral pleura, and the chest wall, termed the parietal pleura. As the pleura forms a contiguous layer with immense surface area, tumors that involve the pleural space do not have an anatomical barrier and have the ability to diffusely spread to cover the entire surface of the chest wall, lung, pericardium, and mediastinum. Such pleural spread is particularly lethal due to the large surface area of involvement and the proximity of the pleura to critical mediastinal thoracic structures. NSCLC can secondarily disseminate to the pleural through direct extension or hematologic spread. [6] The treatment of NSLCC with pleural dissemination is generally palliative in nature. Patients with NSCLC that involves the pleura can present with nodular dissemination of disease and/or a malignant pleural effusion. Such disease commonly is associated with symptoms of dyspnea and pain. [7] [8] In addition to cancer-directed therapy, dyspnea can be managed through the management of the pleural fluid, whereas pain can be managed with analgesics. However, pain medication continues to be underutilized among oncology patients [9] [10] , particularly in those with NSCLC. [11] Chemotherapy without local therapy is the standard therapeutic approach for pleural metastasis of NSCLC. However, chemotherapy alone is associated with a median survival of under a year in this patient population. [5] Unlike surgery [12] , radiotherapy [13] , or ablative therapies like Nd:YAG laser therapy or photodynamic therapy (PDT) [14] that can be used as definitive treatment for localized NSCLC, local therapy is not commonly employed for NSCLC that metastasizes to the pleura. As pleural dissemination is typically very diffuse and can coat and contaminate all surfaces in the chest cavity, definitive resection alone is typically inadequate. Prior reports on surgical resection showed little impact on overall survival and high local failure rates of up to 90% with surgery for NSCLC with pleural metastasis. [15] [16] [17] [18] [19] Intraoperative PDT can attempt to sterilize microscopic residual disease left at the time of surgical resection. PDT combines a photosensitizer, oxygen, and visible light to achieve anticancer directed local therapy. PDT works by direct cell killing via apoptosis or necrosis and also by damaging tumor vasculature. [14, 20] The photosensitizing agent that has been most commonly employed to treat patients with NSCLC is porfimer sodium. This drug is approved by the U.S. Food and Drug Administration to treat NSCLC.
It is unclear if intraoperative PDT can improve local pleural control compared with surgery alone, and if an improvement in local control could lead to an improvement in overall survival for patients with NSCLC with pleural metastasis. Prior attempts to demonstrate an improvement in local control or overall survival with PDT as an intraoperative adjuvant combined with definitive surgery to treat pleural malignancies have not been successful, perhaps due, in part, to limited ability to perform real-time dosimetry and ensure adequate and even light distribution throughout the chest cavity. [21] We conducted a stratified phase II trial assessing the efficacy of definitive surgery and intraoperative PDT in patients with NSCLC with pleural dissemination, and we demonstrating prolonged local control and a much higher than expected 21.7-month median overall survival from the time of surgery and PDT among 22 enrolled patients. [22] This is the first ever report describing optimal methods, techniques, and dosimetry that could be used to safely and reproducibly deliver intraoperative PDT to the chest cavity as part of multimodality therapy for NSCLC with pleural metastasis.
MATERIALS AND METHODS

Patient Selection
Patients with a histologic diagnosis of NSCLC and pleural involvement who are medical suitability for resection and at least 18 years of age could be considered for definitive surgical resection and intraoperative PDT. Patients being considered for this therapy should be excluded for clinical N3 nodal metastasis, extrathoracic metastasis, WBC less than 3,500/mm 3 , platelet count less than 100,000/mm 3 , serum creatinine greater than or equal to 2.5 mg/dL, severe liver disease, bilirubin in excess of 1.5 mg/dL, or being pregnant or lactating.
Workup for eligibility should include a preoperative history and physical examination, laboratory studies, and imaging studies that include a chest CT and/or chest magnetic resonance imaging, CT scan of the abdomen and pelvis and/or PET/CT to exclude extrathoracic disease, and neuroimaging to exclude intracranial metastasis. Patients should also undergo pulmonary function testing.
Chemotherapy and Radiotherapy
Although not required and not uniformly delivered as part of our phase II protocol [22] , we recommend that patients received 2-6 cycles of neoadjuvant chemotherapy prior to definitive surgery. Patients should be considered for a platinum-based doublet of either cisplatin or carboplatin and a second agent that could include etoposide, taxol, or another cytotoxic drug. Preoperative radiation therapy is not routinely recommended but could be administered at the discretion of the treating radiation oncologist. This therapy should be most considered for marginally resectable tumors.
Patients should also be strongly considered for consolidation chemotherapy following surgical resection, as well as sequential adjuvant radiation therapy delivered after chemotherapy that is directed to the mediastinum, hilum, and surgical stump for patients with pathologic N2 nodal disease. In cases of residual disease following surgery, adjuvant radiation therapy to a more comprehensive target volume that includes sites of residual disease and nodes should be used and should be delivered concurrently with chemotherapy, as medically appropriate.
Surgical Procedure
The surgical technique has previously been described for NSCLC with pleural dissemination [22] and other pleural-based malignancies. [23] [24] In all cases, surgery should be performed to remove all visible and palpable tumor from the affected hemithorax. As with oncologic surgeries for most malignancies, outcomes are best when a complete or macroscopic total resection is achieved. This is particularly important prior to delivering intraoperative PDT since the depth of penetration of PDT is finite, and the treatment efficacy will be limited when more bulky gross disease remains after surgical resection.
A thoracotomy through either the sixth interspace or the bed of the resected seventh rib may be most optimal to allow for adequate access to the diaphragm for tumor debulking. The primary parenchymal tumor should be managed according to the same criteria that would be used to determine the extent of resection with curative intent for patients with early stage or locally advanced NSCLC. In general, we recommend lobectomy over a sublobar resection to attempt to maximize local control. [25] When possible, pnuemonectomy should be avoided to limit patient morbidity. In some cases, however, due to the nature of this disease and its diffuse involvement, pnuemonectomy may be required to achieve a gross total resection. In an attempt to minimize morbidity and risk of perioperative mortality, careful consideration should be had when considering the combination of definitive surgery and intraoperative PDT when a pnuemonectomy is likely needed, particularly for patients with right-sided disease. [26] To manage pleural metastases, tumor should be mobilized off the bony hemithorax and posterior and superior mediastinum. The phrenic nerve should be stripped and preserved whenever possible. The pericardial fat, however, usually requires resection. Tumor should be stripped from the diaphragm and pericardium, but these structures should be maintained whenever possible to prevent tumor seeding of their bordering cavities. A complete mediastinal lymphadenectomy should also be performed. Prior to beginning intraoperative PDT, the chest cavity should be irrigated to remove as much residual blood as possible and hemostasis should be achieved so as to limit patient morbidity and not interfere with light delivery.
Photodynamic Therapy Mechanisms of Action and Photosensitizer Choice
Although PDT can achieve cytotoxic effects through a variety of mechanisms, perhaps the greatest contributing mechanism and the one that is best understood and studied is type II reactions that rely on the generation of singlet oxygen and other reactive oxygen species. The reaction of these species with targets in the cell can lead to therapeutic effect. First, a photon of visible light is absorbed by the sensitizer in its singlet ground state, termed S0. As a result of this absorption, the sensitizer is excited to its first excited state, termed S1. Photosensitizers can spontaneously decay from the singlet excited state S1 to an excited triplet state, termed T1. T1 state sensitizer molecules can collide with ground state molecular oxygen molecules, denoted 3 O2, and transfer energy to them, which excites the oxygen molecule to its singlet state, denoted 1 O2, and returns the sensitizer molecule to its ground state. Typically, many molecules of 1 O2 can be produced by a single molecule of photosensitizer without consuming the sensitizer itself. Once generated, 1 O2 typically reacts quickly. There are pathways that do not produce 1 O2 but that allow for direct relaxation from the S1 state to the S0 state though the admission of a visible fluorescent photon. The majority of photosensitizers used clinically are fluorescent [27] [28] .
Optimal photosensitizers must absorb light efficiently in the region of the optical spectrum where most PDT treatments are delivered between 630 nm and 770 nm. Photosensitizers should have a high rate of uptake by target tissues to allow for the therapeutic effect, and this uptake should be higher than for that of normal tissues to allow for a reduction in photosensitivity and limit side effect in patients. Photosensitizers should also allow for a high yield of singlet oxygen, and thus a high triplet oxygen yield, a high likelihood of collisional excitation with ground state oxygen, and also an adequate supply of ground-state oxygen. Photosensitizers should also readily be able to convert the energy of its excited triplet state to excitation of singlet oxygen.
In our prospective trial of surgery and intraoperative PDT for treating NSCLC with pleural dissemination, we employed porfimer sodium as the photosensitizer. Most photosensitizers in widespread clinical use have been derived from organic molecules related to the porphyrins. [29] Hematoporphyrin derivative, known as HpD, was the first clinically viable sensitizer and is a mixture of porphyrins derived from blood. [30] HpD was refined to produce porfimer sodium, which remains as one of the most widely utilized and clinically successful photosensitizers in treating a large variety of malignant, pre-malignant, and benign conditions.
Photodynamic Therapy Light Delivery Devices
Systems used to deliver light for PDT treatments should deliver as uniform of a light distribution as possible throughout the entire treatment field. Many light delivery systems widely utilized in clinical practice are based on lasers coupled to optical fibers terminated in delivery devices. Generally, surface applications employ collimating lenses, interstitial and intracavitary applications employ diffusers, and intraocular applications employ focusing optics. Of note, light emitting diode systems are increasingly being used as an alternative to optical fiber base delivery systems.
Although more simplistic PDT light delivery has been well established for administering a uniform light field to a surface using an optical fiber with collimating optics or for interstitial or interluminal applications for administering light to the center of a bulky tumor or organ using an optical fiber with a diffusing segment at the distal end [31] , PDT of large cavities requires the ability to deliver a uniform distribution of light over the interior surface of a cavity. Intracavity intraoperative PDT, as is done in the chest cavity for pleural dissemination of NSCLC, is particularly challenging since the PDT is performed in a cavity opened by a surgical procedure and the light distribution must be kept uniform while the cavity is generally nonspherical.
Photodynamic Therapy Dosimetry and Procedures
Prior investigations of intracavitary thoracic PDT have been limited by difficulties in the development of models of dosimetry, which is the quantification of dose deposited by the combination of sensitizer and light. PDT-mediated cytotoxic effects vary according to light distribution, photosensitizer, and oxygen, and each of these variables can vary independently and widely, especially in an open chest cavity. Additionally, light distribution is dependent on the absorption and scattering coefficients. [32] Prior to PDT light delivery, patients should receive porfimer sodium 2.0 mg/kg. In keeping with the manufacturer's instructions, the drug should be reconstituted in either 5% dextrose or 0.9% sodium chloride solution to a final concentration of 2.5 mg/ml and infused intravenously over 5-15 minutes approximately 24 hours (range 18-30 hours) prior to intraoperative PDT light delivery.
The distribution and total dose of light delivered should be monitored with isotropic light detectors (Medlight, SA, Switzerland) with an accuracy of + 15%. These detectors should be connected to photodiodes (Photop UDT-455, Graseby Electronics, Orlando, FL, USA), the output of which is converted and stored electronically on a computer and displayed on screens in the operating room. The fluence rate should be assessed in real time for 16 channels simultaneously and integrated fluence measurements should be obtained.
The probes measure both direct incident and scattered light and should be calibrated in air in an integrating sphere with a diffuse light field. The probes should be placed in sterile polyethylene lockable extension tubes and filled with saline that matches the refractive index of the surrounding medium. Probes should be placed in numerous locations throughout the thoracic cavity to ensure a homogenous dose is delivered throughout the chest cavity and an overdose does not occur. We suggest using 8 probes at the following locations: apex, posterior mediastinum, pericardium, diaphragm, anterior sulcus of the diaphragm, posterior sulcus of the diaphragm, anterior chest wall, and posterior chest wall.
Once all of the probes are sewed in place and checked to confirm their recording of light, a dilute intralipid solution (0.01%) should be placed in the pleural cavity that serves to scatter light and to allow for more homogeneous delivery of light throughout the chest cavity. This intralipid solution should be changed regularly to keep the intrathoracic chest cavity as clear as possible and minimize absorption of light by hemoglobin. Red light at 630 nm should be delivered to the pleural surface with an optical fiber sheathed within a modified endotracheal tube or other balloon device (Figure 1 ). The balloon cuff should be inflated and filled with a less dilute intralipid solution (0.1%), which serves to provide light diffusion, prevent tissues from developing thermal burns, and protect the pleural surface from trauma from what would otherwise be a sharp tip of the optical fiber.
A total dose of 60 J/cm 2 of 630 nm light should be delivered to all sites, as measured by the isotropic detectors, to the entire pleural surface and chest cavity. The source of light administration can be variable, and we employed a spherical diffusing fiber (Medlight SA, Switzerland) in our phase II trial. This fiber should be placed in a sterile tube. The primary laser system used in our study was a KTP/532 Laser System (Laserscope, Inc., San Jose, CA, USA).
Vital signs should be monitored during the operative procedure and the perioperative periods. Light precautions should importantly be maintained from the time of photosensitizer administration thorough out the time the patient enters the hospital, the surgical suite, and the recovery and patient care units. The room lights in the surgical suite and the surgeons' headlights should be modified by amber filters (Roscoe, Hollywood, CA, USA) to minimize unwanted activation of the photosensitizing drug and inadvertent light exposure to patients. These filters blocks wavelength below 550 nm, and thus avoid light absorption by porphyrin in the UV and blue-green range. Sterile blue towels should also be used to shield incisions from inadvertent light exposure, whereas the remainder of the patient's skin should be draped per usual surgical procedures and with standard sterile precautions to further avoid inadvertent exposed to light. Finger pulse-oximeters should be rotated between fingers at least every 15 minutes to avoid nail bed burns. Appropriate goggles to attenuate light should be worn by operating room personnel when the laser light is on. Figure 1 . Red light at 630 nm is delivered to the pleural surface using an optical fiber sheathed within a modified endotracheal tube. The balloon cuff of endotracheal tube is inflated and filled with 0.1% diluted intralipid solution to provide light diffusion, prevent tissues from developing thermal burns, and protect the pleural surface from trauma from what would otherwise be a sharp tip of the optical fiber.
DISCUSSION
PDT has been investigated and successfully used as monotherapy and as part of multimodality therapy to treat a variety of premalignant and malignant conditions, including malignant pleural diseases. In a stratified phase II trial assessed the efficacy of definitive surgery and intraoperative PDT, patients with NSCLC with pleural dissemination demonstrated prolonged local control and a higher than expected 21.7-month median survival from the time of surgery and PDT. This is in comparison to the overall median survival of 6-9 months for patients with NSCLC with pleural metastasis. The outcomes of the phase II trial are significantly better than prior studies employing definitive surgery with the intent to remove all visible and palpable gross disease from the affected hemithorax, and they are also more successful than prior surgical series that employed intraoperative PDT to attempting to sterile microscopic residual disease after surgical resection. The improvement in outcomes could be related to advances in PDT dosimetry and procedures. This study reports, for the first time, the optimal methods, techniques, and dosimetry that could be used to safely and reproducibly deliver intraoperative PDT to the chest cavity as part of multimodality therapy for NSCLC with pleural metastasis. Patients were administered porfimer sodium as the photosensitizer using a 24 hour drug-light interval and were treated with PDT to 60 J/cm 2 of 630 nm light, as measured by isotropic detectors sewed into the chest cavity, to the entire pleural surface and chest cavity. When delivery with modern techniques that include real-time dosimetry, as described in this report, the combination of surgery and intraoperative PDT can achieve durable pleural control and prolong survival for patients with NSCLC with pleural dissemination. Patients with stage IVA NSCLC with pleural dissemination treated with neoadjuvant chemotherapy that have good performance statuses and disease limited to one hemithorax could be considered this approach of definitive surgery and intraoperative PDT.
